Oppenheimer & Co. Inc. Sells 37,448 Shares of Hims & Hers Health, Inc. $HIMS

Oppenheimer & Co. Inc. lowered its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 83.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,254 shares of the company’s stock after selling 37,448 shares during the period. Oppenheimer & Co. Inc.’s holdings in Hims & Hers Health were worth $236,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the company. Quent Capital LLC purchased a new position in shares of Hims & Hers Health during the third quarter worth approximately $28,000. Flagship Harbor Advisors LLC purchased a new position in shares of Hims & Hers Health during the fourth quarter worth approximately $28,000. Binnacle Investments Inc purchased a new position in shares of Hims & Hers Health during the third quarter worth approximately $28,000. Bogart Wealth LLC increased its position in shares of Hims & Hers Health by 235.8% during the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after acquiring an additional 632 shares during the period. Finally, Geneos Wealth Management Inc. purchased a new position in shares of Hims & Hers Health during the first quarter worth approximately $30,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $28.46 on Monday. The firm has a market cap of $6.49 billion, a price-to-earnings ratio of 55.81, a PEG ratio of 3.85 and a beta of 2.43. The company’s 50 day moving average is $22.56 and its 200 day moving average is $29.75. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80. Hims & Hers Health, Inc. has a 52-week low of $13.74 and a 52-week high of $70.43.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.06. The company had revenue of $617.82 million for the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. Hims & Hers Health’s revenue was up 28.4% compared to the same quarter last year. During the same period last year, the company posted $0.11 earnings per share. On average, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.53 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Soleil Boughton sold 9,463 shares of Hims & Hers Health stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $30.00, for a total transaction of $283,890.00. Following the transaction, the insider directly owned 299,368 shares of the company’s stock, valued at $8,981,040. This trade represents a 3.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Irene Becklund sold 5,529 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $136,511.01. Following the transaction, the insider directly owned 8,752 shares in the company, valued at approximately $216,086.88. The trade was a 38.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 204,857 shares of company stock valued at $5,285,706. 11.76% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

HIMS has been the topic of a number of research reports. JPMorgan Chase & Co. initiated coverage on shares of Hims & Hers Health in a research report on Friday, April 24th. They set an “overweight” rating and a $35.00 target price on the stock. Evercore set a $24.00 target price on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Barclays raised their target price on shares of Hims & Hers Health from $25.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 11th. BTIG Research lowered shares of Hims & Hers Health from a “buy” rating to a “neutral” rating in a research report on Tuesday, February 24th. Finally, Truist Financial reaffirmed a “hold” rating and set a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Hims & Hers Health has an average rating of “Hold” and an average target price of $31.86.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.